Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...
Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...
More than two months after ransomware shutdown its operations, Japanese food and beverage giant Asahi Holdings continues to suffer from back-office disruptions and was recently forced to acknowledge ...
The following slide deck was published by Recursion Pharmaceuticals, Inc. in conjunction with this event.
Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...
Hosted on MSN
Massive tail and anti-tail jets reveal unexpected structure of interstellar comet 3I/ATLAS
New images of the interstellar object 3I/ATLAS have captured an astonishing, multi-jet structure, with vast plumes extending millions of kilometers into space. The discovery, observed by Frank ...
Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...
The proliferation of observational and interventional research in the fields of sports medicine and orthopaedics has resulted in a rapid expansion of available knowledge. However, as the volume of ...
PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback